Amyloidosis Research Consortium Inc
Newton, Massachusetts
Financial Health Score
9-metric score across financial health, operational efficiency, and organizational resilience. Based on IRS Form 990 data.
Very Good
Financial Trends
5-Year Trend Analysis
Financial Health Indicators
Filing History
9 filings on record| Year | Revenue | Expenses | Assets | |
|---|---|---|---|---|
| 2023 | $2,888,025↑28% | $2,415,059↑13% | $2,975,266↑18% | — |
| 2022 | $2,260,256↑37% | $2,129,932↑27% | $2,516,230↑7% | — |
| 2021 | $1,647,972↓22% | $1,682,131↑36% | $2,350,923↑3% | — |
| 2020 | $2,125,459↑25% | $1,233,948↓7% | $2,277,557↑63% | — |
| 2019 | $1,697,298↑20% | $1,328,269↓20% | $1,394,467↓10% | — |
| 2018 | $1,416,444↑11% | $1,659,988↑83% | $1,548,310↑44% | — |
| 2017 | $1,278,010↑58% | $905,160↑37% | $1,077,608↑73% | — |
| 2016 | $811,069↑8% | $658,640↑115% | $623,943↑34% | — |
| 2015 | $750,022 | $305,982 | $467,346 | — |
Frequently Asked Questions
What does Amyloidosis Research Consortium Inc do?▼
Amyloidosis Research Consortium Inc is a medical research nonprofit organization based in Massachusetts. It is classified under NTEE code H80 and is registered as a 501(c) tax-exempt organization with the IRS.
Is Amyloidosis Research Consortium Inc financially healthy?▼
Based on our 9-metric Financial Health Score model, Amyloidosis Research Consortium Inc has a score of 83/100 (Grade: A-). This score evaluates working capital, surplus consistency, debt ratio, revenue trends, program spending, fundraising efficiency, executive compensation, revenue diversification, and vulnerability indicators.
How much revenue does Amyloidosis Research Consortium Inc generate?▼
Amyloidosis Research Consortium Inc reports $3.4M in annual revenue and holds $4.7M in total assets, based on IRS filings.
Similar Organizations
Explore more organizations in the Medical Research category, or browse all nonprofits in Massachusetts.